×
About 17,505 results

ALLMedicine™ Lymphomas Center

Research & Reviews  5,926 results

A phase I/II trial of brentuximab vedotin plus rituximab as frontline therapy for patie...
https://doi.org/10.1080/10428194.2021.1957867
Leukemia & Lymphoma; Pearse WB, Petrich AM et. al.

Aug 3rd, 2021 - Treatment strategies for post-transplant lymphoproliferative disorders (PTLD) consist of response-adapted risk-stratified methods using immunosuppression reduction, immunotherapy, and chemotherapy. We investigated the efficacy of Brentuximab vedot...

High-grade Follicular Lymphomas Exhibit Clinicopathologic, Cytogenetic, and Molecular D...
https://doi.org/10.1097/PAS.0000000000001726
The American Journal of Surgical Pathology; Laurent C, Adélaïde J et. al.

Aug 3rd, 2021 - Although follicular lymphoma (FL) is usually graded as FL1-2, FL3A, and FL3B, some borderline cases can be observed and led us to investigate the clinicopathologic diversity of grade 3 FL (FL3). Among 2449 FL patients enrolled in Lymphoma Study As...

Primary Mediastinal B-Cell Lymphoma: A 2021 Update on Genetics, Diagnosis, and Novel Th...
https://doi.org/10.1016/j.clml.2021.06.012
Clinical Lymphoma, Myeloma & Leukemia; Ahmed Z, Afridi SS et. al.

Aug 1st, 2021 - Primary mediastinal large B-cell lymphoma (PMBCL) is an aggressive B-cell lymphoma arising from thymic B-cells having clinicopathologic features distinct from systemic diffuse large B-cell lymphoma (DLBCL). PMBCL comprises 2% to 4% of all non-Hodg...

Effective Cytotoxicity of Dendritic Cells against Established T Cell Lymphomas in Mice.
https://doi.org/10.4049/jimmunol.2001123
Journal of Immunology (Baltimore, Md. : 1950); Dubois S, Waldmann TA et. al.

Aug 1st, 2021 - T cell lymphomas arise in mice that constitutively express a single TCR in the absence of NK cells. Upon TCR engagement these lymphomas are able to corrupt tumor surveillance by decreasing NK cell numbers. In this study, we investigate the outcome...

Quality of life in patients with Mycosis Fungoides and Sézary Syndrome: a systematic re...
https://doi.org/10.1111/jdv.17570
Journal of the European Academy of Dermatology and Venere... Ottevanger R, van Beugen S et. al.

Aug 1st, 2021 - Cutaneous T-cell Lymphoma's (CTCL) are a rare, heterogenous group of T-cell lymphomas that primarily manifest in the skin. Mycosis fungoides (MF) and Sézary syndrome (SS) are considered the claswsic types of CTCL. The diverse manifestation of CTCL...

see more →

Guidelines  21 results

Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and...
https://doi.org/10.1016/j.annonc.2019.10.010
Annals of Oncology : Official Journal of the European Soc... Zucca E, Arcaini L et. al.

Jan 9th, 2020 - Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.|2020|Zucca E,Arcaini L,Buske C,Johnson PW,Ponzoni M,|diagnosis,epidemiology,therapy,

Primary extranodal lymphoma of the glands. Literature review and options for best pract...
https://doi.org/10.1016/j.critrevonc.2019.01.005
Critical Reviews in Oncology/hematology; Belkacemi Y, Sio TT et. al.

Mar 2nd, 2019 - Primary extranodal non-Hodgkin's lymphomas (EN-NHL) are a heterogeneous group of malignancies that involve numerous entities with significant difference in terms of tumor site locations, prognostic factors, biology expression, and therapeutic opti...

British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for ...
https://doi.org/10.1111/bjd.17240
The British Journal of Dermatology; Gilson D, Whittaker SJ et. al.

Dec 19th, 2018 - British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous lymphomas 2018.|2018|Gilson D,Whittaker SJ,Child FJ,Scarisbrick JJ,Illidge TM,|methods,standards,methods,standards,therapy,t...

Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment...
https://doi.org/10.1093/annonc/mdy133
Annals of Oncology : Official Journal of the European Soc... Willemze R, Hodak E et. al.

Jun 8th, 2018 - Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.|2018|Willemze R,Hodak E,Zinzani PL,Specht L,Ladetto M,|methods,standards,administration & dosage,standards,genetics,genetics,methods,methods,sta...

Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2017.0165
Journal of the National Comprehensive Cancer Network : JN... Wierda WG, Byrd JC et. al.

Nov 10th, 2017 - Hairy cell leukemia (HCL) is a rare type of indolent B-cell leukemia, characterized by symptoms of fatigue and weakness, organomegaly, pancytopenia, and recurrent opportunistic infections. Classic HCL should be considered a distinct clinical entit...

see more →

Drugs  291 results see all →

Clinicaltrials.gov  329 results

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
https://clinicaltrials.gov/ct2/show/NCT02465060

May 6th, 2020 - PRIMARY OBJECTIVE: I. To evaluate the proportion of patients with objective response (OR) to targeted study agent(s) in patients with advanced refractory cancers/lymphomas/multiple myeloma. SECONDARY OBJECTIVES: I. To evaluate the proportion of pa...

Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
https://clinicaltrials.gov/ct2/show/NCT03210714

May 5th, 2020 - PRIMARY OBJECTIVES: I. To determine the objective response rate (ORR; complete response + partial response) in pediatric patients treated with JNJ-42756493 (erdafitinib) with advanced solid tumors (including central nervous system [CNS] tumors), n...

Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
https://clinicaltrials.gov/ct2/show/NCT03220035

May 5th, 2020 - PRIMARY OBJECTIVES: I. To determine the objective response rate (ORR; complete response + partial response) in pediatric patients treated with vemurafenib with advanced solid tumors (including central nervous system [CNS] tumors), lymphomas or his...

Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas
https://clinicaltrials.gov/ct2/show/NCT03220022

May 5th, 2020 - PRIMARY OBJECTIVES: I. To assess the safety and tolerability of ibrutinib and rituximab (R)-dose adjusted (da)-etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin hydrochloride (EPOCH) in participants with acquired immuno...

Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH ...
https://clinicaltrials.gov/ct2/show/NCT03213665

May 5th, 2020 - PRIMARY OBJECTIVES: I. To determine the objective response rate (ORR; complete response + partial response) in pediatric patients treated with tazemetostat with advanced solid tumors (including central nervous system [CNS] tumors), lymphomas or hi...

see more →

News  430 results

Diagnostic Technology Is Great...Until It Isn't
https://www.medscape.com/viewarticle/954788

Jul 20th, 2021 - "Your exertions below decks were no doubt exhausting." –Caledon Hockley, Titanic, 1997 I once heard of a patient who developed edematous red patches in the skin of her face that looked a lot like the lesion in this photo. This was initially treate...

Latest FDA Pembrolizumab Approval Expands Label to Cutaneous SCCs
https://www.medscape.com/viewarticle/954715

Jul 13th, 2021 - The Food and Drug Administration has approved pembrolizumab (Keytruda) monotherapy for locally advanced cutaneous squamous cell carcinoma (cSCC) that can't be cured by surgery or radiation. The July 6 approval for the programmed death–1 inhibitor ...

FDA Approves Loncastuximab for Diffuse Large B-Cell Lymphomas
https://www.medscape.com/viewarticle/949934

Apr 26th, 2021 - The US Food and Drug Administration granted an accelerated approval April 24 for a new drug for use in patients with relapsed/refractory diffuse large B-cell lymphomas (DLBCL) who have tried at least two prior systemic therapies. The new product, ...

CAR T-cell Products Shine in Real-World Setting, Reveal New Insights
https://www.medscape.com/viewarticle/946240

Feb 22nd, 2021 - Real-world experience with chimeric antigen receptor (CAR) T-cell therapies for large B-cell lymphomas compares favorably with experience in commercial and trial settings and provides new insights for predicting outcomes, according to Paolo Corrad...

FDA Approves Umbralisib (Ukoniq) for Two Lymphomas
https://www.medscape.com/viewarticle/945426

Feb 8th, 2021 - The US Food and Drug Administration (FDA) has granted accelerated approval to umbralisib (Ukoniq) for the treatment of adults with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen and...

see more →

Patient Education  5 results see all →